ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer

Area of Science:

• Thoracic Surgery
• Oncology
• Diagnostic Imaging

Background:

• Accurate preoperative staging of mediastinal lymph nodes is critical for non-small cell lung cancer (NSCLC) management, influencing treatment decisions and patient outcomes.
• Various diagnostic techniques exist, differing in accuracy and morbidity, necessitating updated guidelines.

Framework:

• European Society of Thoracic Surgeons (ESTS) workshop established guidelines for primary and restaging of mediastinal lymph nodes in NSCLC.
• Mediastinoscopy remains the gold standard for superior mediastinal lymph node staging.

Implementation:

• Invasive staging can be omitted for peripheral tumors with negative PET scans, but is indicated for central tumors, PET-positive findings, or large lymph nodes (> or = 16 mm).
• Minimally invasive techniques like EBUS-FNA and EUS-FNA offer high specificity but low negative predictive value, requiring confirmation with invasive methods if negative.
• PET-positive findings necessitate cyto-histological confirmation; positive results from fine needle aspiration can confirm N2 or N3 disease.

Implications:

• For restaging, invasive techniques with cyto-histological confirmation are advised, even with advances in PET/CT imaging.
• Positive results from restaging guide towards non-surgical treatment options for most patients.